<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="rapid-communication" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6627469</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.9b00303</article-id><article-categories><subj-group><subject>Brief Article</subject></subj-group></article-categories><title-group><article-title>Enhanced Inhibition of Influenza A Virus Adhesion
by Di- and Trivalent Hemagglutinin Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Lu</surname><given-names>Wenjing</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes2" ref-type="notes">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Du</surname><given-names>Wenjuan</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Somovilla</surname><given-names>Victor J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Yu</surname><given-names>Guangyun</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Haksar</surname><given-names>Diksha</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>de Vries</surname><given-names>Erik</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Boons</surname><given-names>Geert-Jan</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>de Vries</surname><given-names>Robert P.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath9"><name><surname>de Haan</surname><given-names>Cornelis A. M.</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><name><surname>Pieters</surname><given-names>Roland J.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Chemical Biology &#x00026; Drug Discovery, Utrecht Institute for Pharmaceutical
Sciences, <institution>Utrecht University</institution>, P.O. Box 80082, NL-3508 TB Utrecht, <country>The Netherlands</country></aff><aff id="aff2"><label>&#x02021;</label>Virology
Division, Department of Infectious Diseases and Immunology, Faculty
of Veterinary Medicine, <institution>Utrecht University</institution>, NL-3584 CL Utrecht, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="cor2"><label>*</label>C.A.M.d.H.: e-mail, <email>C.A.M.deHaan@uu.nl</email>; phone, <phone>+31302534195</phone>.</corresp><corresp id="cor1"><label>*</label>R.J.P.: e-mail <email>R.J.Pieters@uu.nl</email>; phone, <phone>+31620293387</phone>.</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>06</month><year>2019</year></pub-date><pub-date pub-type="ppub"><day>11</day><month>07</month><year>2019</year></pub-date><volume>62</volume><issue>13</issue><fpage>6398</fpage><lpage>6404</lpage><history><date date-type="received"><day>15</day><month>02</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 American Chemical
Society</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0006" id="ab-tgr1"/></p><p>Multivalent carbohydrate-based ligands
were synthesized and evaluated
as inhibitors of the adhesion protein HA of the influenza A virus
(IAV). HA relies on multivalency for strong viral adhesion. While
viral adhesion inhibition by large polymeric molecules has proven
viable, limited success was reached for smaller multivalent compounds.
By linking of sialylated LAcNAc units to di- and trivalent scaffolds,
inhibitors were obtained with an up to 428-fold enhanced inhibition
in various assays.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm9b00303</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm-2019-003037</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Influenza A virus (IAV)
causes the flu and poses a serious threat
to human health. History has shown that the flu can lead to serious
pandemics, with millions of deaths in 1918<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and a risk of future outbreaks of deadly variants.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> IAV contains two envelope glycoproteins that bind to sialylated
glycans. The hemagglutinin (HA) is responsible for attachment of the
virus to the tissue surface to be infected, and its specificity lies
at the origin of the species specificity and tissue tropism of the
virus, while it is also of importance for the viral fusion with the
endosome.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> The neuraminidase (NA) is a
glycosidase enzyme that removes the sialic acid group from glycans
which leads to a release of the HA-based attachment<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and allows the virus to burrow through the protective mucosa
and enter the cell. Importantly, the NA also allows the progeny virions
to be released from the cell surface to infect other cells. A functional
balance is needed between the binding and cleavage properties of NA
and HA.<sup><xref ref-type="bibr" rid="ref4">4</xref>&#x02212;<xref ref-type="bibr" rid="ref6">6</xref></sup></p><p>IAVs cause seasonal epidemics and occasional
pandemics. The latter
are caused by animal viruses that managed to cross the animal&#x02013;human
species barrier. Prophylactic and therapeutic options against influenza
are limited. Several approaches are being used, the most common of
which is the vaccination strategy. This is a valuable approach for
the seasonal IAV variants that are very common and infective, yet
usually only life threatening for those with weakened immune systems.
Vaccination is complicated by the large antigenic variation in HA
and NA with currently 16 HA and 9 NA subtypes of varying antigenicity
known.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Also within HA and NA subtypes
changes in antigenicity resulting from mutational variation (antigenic
drift) are observed. Nevertheless recent progress was reported toward
prophylactic and therapeutic vaccines.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> In case of an epidemic, neuraminidase inhibitors such as oseltamivir
or zanamivir can be used to reduce the illness symptoms and infectivity.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Unfortunately, resistance of IAV to these neuraminidase
inhibitors has been observed<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> which greatly
hampers the effectiveness of the therapy. Similar to the approach
to HIV infections, it will likely be more effective to use a combination
therapy that addresses HA and NA and possibly additional targets.</p><p>While NA was proven to be a druggable target that yielded nanomolar
inhibitors with improved glycomimetic and prodrug characteristics
to overcome some of the challenges of carbohydrate drugs,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> the situation is different for HA. The adhesion
protein binds only with millimolar affinities to sialylated glycan
receptors. Binding has been observed to &#x003b1;2,6-SiaLAcNAc for the
human type specific HAs or &#x003b1;2,3-SiaLAcNAc for avian type-specific
HAs.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup> The low affinities are
a challenging starting point for a carbohydrate based drug development
program, but also non-carbohydrate approaches have faced this challenge.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> The virus, however, binds with high affinity
to tissue surfaces by using multivalency,<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> which increases its avidity to levels that enable infection. The
multivalency effects involve the simultaneous binding of glycans to
more than one of the three binding sites per HA trimer on the IAV
surface but also the simultaneous binding of cell surface glycans
to multiple HA protein trimers on the viral surface. The overall avidity
effects are very strong<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> and crucial for
IAV. In that sense it is a logical step to attempt to block the viral
infection via the HA protein with a multivalent inhibitor.</p><p>We
here describe our use of di- and trivalent scaffolds as multivalent
scaffolds to inhibit IAV (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(a) Top view of an X-ray structure of an HA trimer protein
bound
to three molecules of &#x003b1;-2,3-SiaLac (PDB code 1HGG).<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> (b) Schematic tripodal ligand design for the chelation
type inhibition of influenza virus A hemagglutinin protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0001" id="gr1" position="float"/></fig><p>These scaffolds were extended
with &#x003b1;2,6-SiaLacNAc linked
to lactose. The largest of the compounds were larger (more atoms in
the spacers between sialic acid units; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>) than a biantennary Sia(LacNAc)<sub>3</sub> linked
to a trimannose core, known for chelation.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> The constructs were evaluated as inhibitors in a viral binding assay
and were shown to be significantly stronger inhibitors than their
monovalent counterparts, and they were hardly affected by neuraminidases.
Finally, they were also shown to inhibit IAV infection.</p><p>Multivalency
as a strategy to enhance binding and inhibition has
been widely explored in protein&#x02013;carbohydrate interactions<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> to bridge binding sites<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> or inhibit
pathogen binding<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> by mechanisms such as
chelation and statistical rebinding.<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref></sup> Indeed several
examples of multivalent sialic acid containing glycans have been reported.
Relatively large molecular entities can take advantage of their size
to bridge multiple HA trimers.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Some of
these have yielded potency enhancements of 3&#x02013;4 orders of magnitude.
Such systems include a polyacrylate carrier,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> polyacrylamide,<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> polyglutamic acid,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> polyglycerol based nanoparticles,<sup><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup> chitosan,<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> and liposomes.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup></p><p>For drug development it would be an advantage
if monodisperse,
small well-defined molecular entities can be used, with no risk of
immunogenicity. Reaching this goal has proven considerably more difficult.
Reported studies by Knowles et al. showed that certain divalent sialiosides,<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> did not exhibit enhanced HA binding when exposed to an HA trimer
but were able to enhance hemagglutination inhibition when the HAs
were present on a viral surface. Their convincing proof showed that
the compounds were able to bridge between HA trimers, an aggregation
mechanism, the benefits of which are not well understood.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Similar observations were made by others including
a system containing two &#x003b1;-2,6-SiaLacNAc units linked via a single
galactoside moiety,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> dendrimers presenting
sialic acids,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> cyclic peptides presenting
sialyl lactosides,<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> and a calixarene linked
to four sialic acids.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> These constructs
resulted in moderate enhancements, and they did not have the structural
features now known to be needed to bridge between binding sites within
an HA trimer (&#x0223c;67 atoms in the bridge between sialic acids).<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> An interesting case is a system based on a trisubstituted
benzene ring linked to sialic acids via peptidic spacer arms. This
construct with the right dimensions to bridge binding sites was reported
to bind to immobilized HA by SPR with a <italic>K</italic><sub>d</sub> of 450 nM.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> However, the peptidic component
showed significant binding indicative of peptide protein interactions
but indeed leading to an overall potent compound. In another system,
a three-way junction DNA for the display of &#x003b1;-2,3-SiaLac units
was shown to be potent, but a single arm was not much less potent.
This is indicative of DNA&#x02013;protein interactions and makes a
bridging mechanism less likely.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> A system
based on PNA-DNA complexes displaying two &#x003b1;-2,6-SiaLacNAc units
at various distances was also reported.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Evidence for true chelation, i.e., bridging between binding sites,
was provided and yielded a &#x0223c;30-fold enhancement (15-fold per
sugar) over a DNA-PNA reference construct containing only a single
glycoligand. Unfortunately, these noncovalent constructs of &#x0223c;21
kDa are not small molecules. Other indications that chelation of HA
binding sites is indeed possible come from carbohydrate array experiments
with biantennary glycans. They showed that glycans with at least three
LacNAc units in each of the arms bound more strongly to human type
specific HAs.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Molecular modeling supported
the chelation mode and indicated that two LacNAc units would be too
short. This chelation type binding was shown to only be possible for
the human type specific HA binding to &#x003b1;2,6-linked sialic acid
for geometrical reasons and is precluded for the &#x003b1;2,3-linked
ones.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup></p><p>On the basis of these clear
indications that chelation is possible,
we directed our efforts to make di- and trivalent ligands for the
HA protein of IAV that can engage more than one of its three binding
sites at the same time.</p></sec><sec id="sec2"><title>Results</title><p>The synthesis started with
the preparations of the building blocks
shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>.
Their detailed syntheses can be found in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>. Compounds <bold>1</bold>&#x02013;<bold>3</bold> are the core or scaffold structures outfitted with azido groups.
The other compounds <bold>4</bold>&#x02013;<bold>8</bold> are the glycans
that contain alkyne groups for linkage to <bold>1</bold>&#x02013;<bold>3</bold> by CuAAC conjugation. Compound <bold>1</bold> represents
a trivalent scaffold derived from a known triamine<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> with the potential to display three glycans toward all
three HA binding sites of the trimer. Compound <bold>2</bold> is a
divalent spacer with rigid elements such as a direct linkage between
glucose and triazole, a motif that was previously explored in rigid
spacers for enhanced multivalency effects.<sup><xref ref-type="bibr" rid="ref41">41</xref>&#x02212;<xref ref-type="bibr" rid="ref43">43</xref></sup> Compound <bold>3</bold> is a polymeric dextran scaffold<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> for comparison with the &#x0201c;small&#x0201d; molecule scaffolds <bold>1</bold> and <bold>2</bold>. Compounds <bold>4</bold>, <bold>5</bold>, and <bold>8</bold> were made from propargyl lactose, and <bold>7</bold> was made from LacNAc, and azidolactose and 1,4-diethynylbenzene
were the starting materials for <bold>6</bold> via CuAAC. The &#x003b2;1,3-linked
GlcNAc and &#x003b2;1,4-linked Gal moieties of <bold>5</bold>, <bold>6</bold>, and <bold>8</bold> were introduced using glycosyl transferases.
Similarly, the &#x003b1;-2,6-linked sialic acid part of <bold>7</bold> and <bold>8</bold> was added using a sialyl transferase.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Structures
of the building blocks used in the synthesis of the
multivalent carbohydrate HA inhibitors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0002" id="gr2" position="float"/></fig><p>The alkyne-linked lactose/LacNAc building blocks <bold>4a</bold>, <bold>5</bold>, and <bold>6</bold> were coupled to the azido scaffolds <bold>1</bold> and <bold>2</bold> via CuAAC conjugation as shown in <xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>. The products were
purified and in one case deprotected (synthesis of <bold>9</bold>)
before the final sialylation with the sialyltransferase enzyme PmSTI
mutant, which was mutated to achieve the desired 2,6 specificity.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> The products were purified by preparative HPLC
to yield the fully sialylated <bold>10</bold>, <bold>12</bold>, <bold>14</bold>, and <bold>17</bold>.</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Synthesis of Multivalent HA Inhibitors</title><p id="sch1-fn1">Reagents and conditions: (a)
CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O, Na ascorbate, DMF/H<sub>2</sub>O (9:1), microwave, 80 &#x000b0;C; (b) NaOMe, MeOH; (c) CMP-NANA, PmSTI
mutant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0005" id="gr3" position="float"/></fig><p>In the sialyation of <bold>13</bold> also the disialylated <bold>15</bold> was obtained and purified
as a useful reference compound.
In our hands, performing the CuAAC conjugation with the sialylated
building blocks such as <bold>7</bold> and <bold>8</bold> was problematic,
which is the reason for the strategy of performing the sialylation
as the last step on the multivalent precursor.</p><p>The inhibition
studies were conducted with the use of a biolayer
interferometry (BLI) assay.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> In this assay
a streptavidin coated sensor was loaded with a sialylated glycoprotein
LAMP1. Influenza A virus WU95 (containing a H3 protein of a human
H3N2 virus; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>)
was used, and its binding to the sensor could readily be observed.
Performing the experiment in the presence of the inhibitors clearly
showed inhibition (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a). By use of a range of concentrations for each compound,
inhibition curves were obtained (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B) and the results were quantified (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(a) Analysis of inhibition
of virus-receptor binding by BLI. Real-time
kinetic analysis of virus binding to LAMP1 was performed by BLI. A
representative experiment of concentration-dependent inhibition of
virus binding by <bold>15</bold> is shown as determined by the BLI
wavelength shift. (b) Inhibition curves of compounds from left to
right, <bold>14</bold> (blue), <bold>15</bold> (red, obstructed by <bold>14</bold>), <bold>18</bold> (purple), <bold>12</bold> (green), <bold>17</bold> (yellow), <bold>10</bold> (orange), <bold>8</bold> (brown),
and <bold>7</bold> (light purple), of the virus-receptor binding determined
similarly as shown in (a).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0003" id="gr4" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Results of IAV Inhibition by Multivalent
Carbohydrates Using BLI and HAI Assays</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">entry</th><th style="border:none;" align="center">construct</th><th style="border:none;" align="center">glycoligand</th><th style="border:none;" align="center">valency</th><th style="border:none;" align="center">IC<sub>50</sub>&#x000a0;BLI (&#x003bc;M)<xref rid="t1fn4" ref-type="table-fn">d</xref></th><th style="border:none;" align="center">rel pot. (per&#x000a0;sugar)<xref rid="t1fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center"><italic>K</italic><sub>i</sub>&#x000a0;HAI (&#x003bc;&#x0039c;)</th><th style="border:none;" align="center">rel pot. (per&#x000a0;sugar)<xref rid="t1fn2" ref-type="table-fn">b</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left">1</td><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="left">SiaLacNAc</td><td style="border:none;" align="left">1</td><td style="border:none;" align="left">304&#x000a0;&#x000b1;&#x000a0;11</td><td style="border:none;" align="left">1&#x000a0;(1)</td><td style="border:none;" align="left">nd<xref rid="t1fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">2</td><td style="border:none;" align="left"><bold>8</bold></td><td style="border:none;" align="left">SiaLacNAcLac</td><td style="border:none;" align="left">1</td><td style="border:none;" align="left">396&#x000a0;&#x000b1;&#x000a0;3</td><td style="border:none;" align="left">1&#x000a0;(1)</td><td style="border:none;" align="left">360&#x000a0;&#x000b1;&#x000a0;139</td><td style="border:none;" align="left">1&#x000a0;(1)</td></tr><tr><td style="border:none;" align="left">3</td><td style="border:none;" align="left"><bold>13</bold></td><td style="border:none;" align="left">LacNAcLac-triazole-Ph</td><td style="border:none;" align="left">3</td><td style="border:none;" align="left">no inhib at 20&#x000a0;&#x003bc;M</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">nd<xref rid="t1fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">4</td><td style="border:none;" align="left"><bold>10</bold></td><td style="border:none;" align="left">SiaLac</td><td style="border:none;" align="left">3</td><td style="border:none;" align="left">15&#x000a0;&#x000b1;&#x000a0;0.3</td><td style="border:none;" align="left">20&#x000a0;(7)</td><td style="border:none;" align="left">53&#x000a0;&#x000b1;&#x000a0;15</td><td style="border:none;" align="left">7&#x000a0;(2)</td></tr><tr><td style="border:none;" align="left">5</td><td style="border:none;" align="left"><bold>17</bold></td><td style="border:none;" align="left">SiaLac</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">13&#x000a0;&#x000b1;&#x000a0;1</td><td style="border:none;" align="left">23&#x000a0;(12)</td><td style="border:none;" align="left">nd<xref rid="t1fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">6</td><td style="border:none;" align="left"><bold>12</bold></td><td style="border:none;" align="left">SiaLacNAcLac</td><td style="border:none;" align="left">3</td><td style="border:none;" align="left">4.3&#x000a0;&#x000b1;&#x000a0;3.7</td><td style="border:none;" align="left">71&#x000a0;(24)</td><td style="border:none;" align="left">nd<xref rid="t1fn3" ref-type="table-fn">c</xref></td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">7</td><td style="border:none;" align="left"><bold>14</bold></td><td style="border:none;" align="left">SiaLacNAcLac-triazole-Ph</td><td style="border:none;" align="left">3</td><td style="border:none;" align="left">0.71&#x000a0;&#x000b1;&#x000a0;0.08</td><td style="border:none;" align="left">428&#x000a0;(143)</td><td style="border:none;" align="left">9.4&#x000a0;&#x000b1;&#x000a0;3.8</td><td style="border:none;" align="left">38&#x000a0;(13)</td></tr><tr><td style="border:none;" align="left">8</td><td style="border:none;" align="left"><bold>15</bold></td><td style="border:none;" align="left">SiaLacNAcLac-triazole-Ph</td><td style="border:none;" align="left">2</td><td style="border:none;" align="left">0.71&#x000a0;&#x000b1;&#x000a0;0.15</td><td style="border:none;" align="left">428&#x000a0;(214)</td><td style="border:none;" align="left">10.3&#x000a0;&#x000b1;&#x000a0;5.6</td><td style="border:none;" align="left">35&#x000a0;(17)</td></tr><tr><td style="border:none;" align="left">9</td><td style="border:none;" align="left"><bold>18</bold></td><td style="border:none;" align="left">SiaLacNAc</td><td style="border:none;" align="left">55</td><td style="border:none;" align="left">1.51&#x000a0;&#x000b1;&#x000a0;0.16</td><td style="border:none;" align="left">201&#x000a0;(4)</td><td style="border:none;" align="left">3.75&#x000a0;&#x000b1;&#x000a0;1.4</td><td style="border:none;" align="left">96&#x000a0;(2)</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Relative to the potency of <bold>7</bold>.</p></fn><fn id="t1fn2"><label>b</label><p>Relative to the potency of <bold>8</bold>.</p></fn><fn id="t1fn3"><label>c</label><p>Not determined.</p></fn><fn id="t1fn4"><label>d</label><p>in the presence of 10 &#x003bc;M oseltamivir
carboxylate.</p></fn></table-wrap-foot></table-wrap><p>First to note
is that the inhibition with the two reference compounds <bold>7</bold> and <bold>8</bold> showed relatively low IC<sub>50</sub>&#x02019;s
below the millimolar level that is commonly associated
with the binding of sialic acid derivatives to whole virus or HA.
Another notable fact is that the inhibition of the two compounds is
very similar, indicating that the added lactose moiety of <bold>8</bold> does not help the binding. Another reference compound was <bold>13</bold>. It contains the triphenylbenzene core linked to the LacNAcLac
arms. The combined presence of the hydrophobic aromatic core and the
12 sugar moieties did not yield any detectable inhibition in the assay
up to the 20 &#x003bc;M used in the assay.</p><p>Compounds <bold>14</bold> and <bold>15</bold> were the most potent
in the assay, with IC<sub>50</sub> of 0.7 &#x003bc;M, representing a
428-fold enhancement over reference <bold>7</bold>. The two compounds
were strikingly similar in the assay, clearly indicating that two
sialic acid groups were sufficient and that simultaneous binding to
all three HA sites with <bold>14</bold> was not achieved. The fact
that both compounds were similar indicates that the expected statistical
advantage of <bold>14</bold> is compensated by other factors. The
trivalent compounds with the shorter linker <bold>12</bold> and shorter
ligand moieties <bold>10</bold> were considerably weaker inhibitors
with IC<sub>50</sub> of 4.3 and 15 &#x003bc;M, respectively, indicating
the importance of the length of the arm. The divalent scaffold <bold>2</bold> contains a similar number of atoms separating the azido
groups as trivalent scaffold <bold>1</bold>. Notably, the compound
based on <bold>2</bold>, i.e., <bold>17</bold>, had very similar potency
when compared to the one derived from <bold>1</bold>, i.e., <bold>10</bold>. This result again indicates that divalent binding is likely.
Furthermore, it indicates the importance of the length of the arm,
as the longer arms lead to enhanced inhibition. Interestingly, the
polymeric glycoconjugate <bold>18</bold>, while a potent inhibitor
with an IC<sub>50</sub> of 1.5 &#x003bc;M, was weaker than the tri-
and divalent <bold>14</bold> and <bold>15</bold> and much more so
when corrected for valency, as the relative potency per sugar is only
3.75.</p><p>In addition to BLI experiments with an H3-containing virus
(WU95),
we analyzed the inhibitory activity of <bold>14</bold> against another
human virus (H1N1) and an avian H5N1 virus. The human H1N1 virus was
efficiently and fully inhibited, although with a somewhat higher IC<sub>50</sub> (2.7 &#x003bc;M) than the H3 containing virus. In contrast
the avian H5N1 virus could be inhibited maximally 50%, which probably
relates to differences in the receptor-binding properties of the different
viruses. The fact that full inhibition of H5N1 was not achieved is
likely caused by this virus preferring binding to &#x003b1;2,3- over
&#x003b1;2,6-linked sialic acids, both of which are present on the glycoprotein
receptor, while the inhibitor contains &#x003b1;2,6-SiaLAcNAc.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup></p><p>The above experiments were run in the
presence of 10 &#x003bc;M neuraminidase
inhibitor oseltamivir carboxylate (OC) to inhibit the neuraminidase
that could potentially cleave off the sialic acid moieties from the
inhibitors. A direct comparison was made between experiments involving
inhibitory concentrations (3 &#x003bc;M) of <bold>14</bold>, <bold>15</bold>, and <bold>12</bold> in the presence of oseltamivir carboxylate,
with the same experiments without the NA inhibitor. These experiments
showed very similar degrees of inhibition. Repeating these experiments
with a different IAV, i.e., VI75 (containing H3 from another H3N2
virus; see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>), showed,
first, similar degrees of inhibition and, second, no effect of oseltamivir
carboxylate.</p><p>Besides the BLI assay, also a hemagglutination
inhibition (HAI)
assay was performed using the H3-containg WU95 virus for a number
of our compounds. Results are shown in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. Overall the results show the same trends
but the <italic>K</italic><sub>i</sub>&#x02019;s for the most potent
compounds <bold>14</bold> and <bold>15</bold> were not as low but
still in the low micromolar range. It should be noted that the conditions
are different in both assays, and especially multivalency effects
can vary due to the in vitro assay conditions.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Notably the receptor density on red blood cells
is considerably higher than present in the BLI assay.</p><p>To further
evaluate the potential of the compounds as IAV inhibitors,
an infection inhibition test was performed using the H3-containing
WU95 virus. As such, MDCK-II cells were exposed to IAV at a multiplicity
of infection (MOI) of 0.005 tissue culture infectious dose 50 (TCID<sub>50</sub>) per cell in the presence and absence of <bold>14</bold> or <bold>12</bold> at different concentrations without the presence
of an NA inhibitor. At 7 h postinfection the number of infected cells
were determined (see <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>), and IC<sub>50</sub> values were determined. In agreement
with the BLI results, <bold>14</bold> (IC<sub>50</sub> = 4.4 &#x003bc;M)
inhibited infection more efficiently than <bold>12</bold> (IC<sub>50</sub> = 15 &#x003bc;M). Furthermore, it was determined that the
two compounds did not cause significant cytotoxicity (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>). In addition, we analyzed
the ability of the compounds to prevent cell killing by virus infection.
Again, <bold>14</bold> was more effective than <bold>12</bold> (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>). Finally, we analyzed
whether synergy could be observed between HA inhibitor <bold>15</bold> and NA inhibitor oseltamivir carboxylate. Low nanomolar concentrations
of each showed little effect, but when they were combined, a significant
reduction of infection was observed (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Infection of MDCK-II cells by H3-containing WU95 virus
in the presence
or absence of <bold>14</bold> and <bold>12</bold>. Inhibition of infection
relative to infection in the absence of compounds is graphed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2019-003037_0004" id="gr5" position="float"/></fig></sec><sec id="sec3"><title>Discussion and Conclusions</title><p>We here
showed the successful synthesis of multivalent sialic acid
containing glycoconjugates. Their synthesis was possible by a combination
of chemical scaffold synthesis, enzymatic carbohydrate synthesis,
and CuAAC conjugation. The well-defined systems were found to inhibit
the binding of IAV in a dose dependent manner. Clearly a combination
of structural features is needed for inhibition as a single sugar
arm is weakly active and the non-sialyl system is not active. Enhancements
of 428-fold were achieved with the system containing two or three
sialic acid units. Furthermore, the use of divalent systems showed
similar results to experiments performed with trivalent systems. Therefore,
not all three binding sites can be occupied simultaneously by our
system, but two seem possible, as previously indicated for large biantennary
glycans<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> and DNA bridged divalent ligands.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The length of the glycan arm is an important
factor in the potency.</p><p>Hemaglutination inhibition experiments
gave the same trends as
the BLI assay, but effects were smaller. A difference was seen in
the degree of inhibition and multivalency effects. Overall the data
are consistent with a bivalent chelating binding mode.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref48">48</xref></sup> As such this is the first example
of a nonmacromolecular compound to demonstrate this and indicates
that with additional optimization a therapeutic avenue is within reach.
Compounds <bold>14</bold> and <bold>12</bold> were tested in infection
inhibition assays and cell killing inhibition assays. In both of these
cases inhibition is clearly observed, and the order of potency is
consistent with that from the BLI assay. Furthermore, no toxicity
was observed for these compounds. In the BLI assay it was remarkable
that no effect of the NA inhibitor oseltamivir carboxylate was observed.
Furthermore, in the infection inhibition assay no NA inhibitor was
added, yet full inhibition was observed. Others<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> have seen a similar nonresponse to NA blocking before and
explained it with (1) the tight inhibitor binding to HA, resulting
in less availability for NA, (2) weak inherent NA activity, especially
on the &#x003b1;-2,6 isomers, and (3) a lower presence of NA compared
to HA. For medical application of this type of NA inhibiting compound
the introduction of an S-linked sialic acid, as previously reported,<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> is nevertheless recommended to ensure sialic
acid cleavage from the inhibitor by NA does not happen. In agreement
herewith, <bold>15</bold> showed a synergistic effect with NA inhibitor
OC. Low nanomolar concentrations of either reagent had no major effect,
but the combination greatly reduced infections. This result supports
the notion of a combination therapy, as practiced for HIV. The multivalent
approach as described here may not be limited to IAV but can likely
be extended to other systems as previously shown for adenovirus.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup></p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>Chemistry</title><p>Compounds <bold>2</bold>,<sup><xref ref-type="bibr" rid="ref42">42</xref></sup><bold>3</bold>,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup><bold>4b</bold><sup><xref ref-type="bibr" rid="ref52">52</xref></sup> and propargyl were synthesized as previously
reported. Yields of individual reactions and spectra data are reported
in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">Supporting Information</ext-link>. All tested
compounds were &#x0003e;95% pure by HPLC.</p></sec><sec id="sec4.1.1"><title>Tris-azide (<bold>1</bold>)</title><p>1,3,5-Tris(3-aminophenyl)benzene<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> (70 mg, 0.2 mmol) was dissolved in DCM (5 mL).
4-Azidobutanoic acid (77 mg, 0.6 mmol, 3 equiv) was added, followed
by DMAP (7.3 mg, 0.06 mmol, 0.3 equiv), EDC&#x000b7;HCl (190 mg, 1.0
mmol, 5 equiv). The mixture was stirred for 48 h at room temperature.
Then the solution was washed with 1 M HCl solution, followed by saturated
NaHCO<sub>3</sub> solution and by saturated NaCl solution. After drying
(Na<sub>2</sub>SO<sub>4</sub>) the solvent was removed, and the residue
was purified using column chromatography over silica gel (eluent DCM/MeOH
75:1 v/v) to give 55 mg (40%) of an off-white solid.</p></sec><sec id="sec4.2"><title>General Procedure
for the Synthesis of LacNAc Sequences in <bold>5</bold> and <bold>6</bold></title><p>The appropriate lactoside (1
equiv, &#x0223c;0.03 mmol) and UDP-GlcNAc (1.5 equiv) were dissolved
in HEPES buffer (50 mM, pH 7.3, 2.5 mL) containing KCl (25 mM), MgCl<sub>2</sub> (2 mM), and dithiothreitol (1 mM). To this, 20 &#x003bc;L of
CIAP (10 mU) and 50 &#x003bc;L of <italic>H. pylori</italic> &#x003b2;3GlcNAcT
(&#x003b2;1-3GlcNAc transferase) were added. The resulting reaction
mixture was incubated at 37 &#x000b0;C for 14 h, followed by Biogel P-2
and silica gel (<bold>6</bold>) purification. The resulting GlcNAc
glycan (0.007&#x02013;0.017 mmol, 1 equiv) and UDP-Gal (1.5 equiv)
were dissolved in MES buffer (100 mM, 300&#x02013;500 &#x003bc;L) containing
MnCl<sub>2</sub> (20 mM). To this, 30&#x02013;50 &#x003bc;L of LgtB (&#x003b2;1-4Gal
Transferase) was added. The resulting reaction mixture was incubated
at 37 &#x000b0;C for 3 h. The reaction mixture was centrifuged, and the
supernatant was purified by gel filtration over Biogel P-2 (eluent
H<sub>2</sub>O).</p></sec><sec id="sec4.3"><title>General Procedure for the Enzymatic 2,6-Sialylation
in the Synthesis
of <bold>7</bold>, <bold>8</bold>, <bold>10</bold>, <bold>12</bold>, <bold>14</bold>, <bold>15</bold>, and <bold>17</bold></title><p>The appropriate LacNAc derivative (1 equiv) and CMP-NANA (1.2&#x02013;3.3
equiv per LacNAc unit) were dissolved in Tris-HCl buffer (100 mM,
pH 7.5, 200&#x02013;500 &#x003bc;L) containing MgCl<sub>2</sub> (20 mM).
To this, PmST1 mutant P34H/M144L (&#x003b1;2-6 sialyltransferase, 20&#x02013;50
&#x003bc;L) was added to the reaction mixture. Then the resulting reaction
mixture was incubated at 37 &#x000b0;C for 4 h. The reaction mixture
was centrifuged and the supernatant subjected to gel filtration over
Biogel P-2 (eluent H<sub>2</sub>O). Fractions containing product were
combined and lyophilized for further preparative HPLC (HILIC column)
for <bold>12</bold>, <bold>14</bold>, <bold>15</bold>, and <bold>16</bold>.</p></sec><sec id="sec4.4"><title>General Procedure for CUAAC Conjugation in the Synthesis of <bold>9a</bold>, <bold>11</bold>, <bold>13</bold>, <bold>16</bold></title><p>The appropriate azido compound (1 equiv) and alkyne (1.3&#x02013;2.3
equiv per azido group), CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (0.04&#x02013;0.5
equiv), sodium <sc>l</sc>-ascorbate (2.5 equiv) were dissolved in
DMF/H<sub>2</sub>O (0.2&#x02013;2 mL). The reaction was performed under
microwave irradiation (80&#x02013;100 &#x000b0;C, 1&#x02013;1.5 h). Then
the mixture was concentrated in vacuo. The residue was purified by
silica chromatography (DCM/MeOH 20:1 v/v) for <bold>9a</bold> and
Biogel P-2 (eluent H<sub>2</sub>O) for the others.</p></sec><sec id="sec4.4.1"><title>Polymer <bold>18</bold></title><p>The azido polymer (<bold>3</bold>) was dissolved
in water followed by the addition of <bold>7</bold> (3 mg, 1.3 equiv).
CuSO<sub>4</sub>&#x000b7;5H<sub>2</sub>O (0.1 equiv)
and sodium <sc>l</sc>-ascorbate (0.3 equiv) were dissolved in water
separately and added to the reaction mixture. The reaction was carried
out at 100 &#x000b0;C with microwave radiation for 60 min. The solvent
was evaporated, and the crude reaction mixture was purified by dialysis
using a cellulose based dialysis cassette (MWCO: 2K) against deionized
water for 3&#x02013;4 days and freeze-dried to give a white compound
(3 mg, 24%). The disappearance of the azide stretching peak in the
IR spectra of the final compound confirmed that all of the azido groups
had reacted.</p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge on the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.9b00303">10.1021/acs.jmedchem.9b00303</ext-link>.<list id="silist" list-type="simple"><list-item><p>Experimental details
of the synthesis, characterization,
and compound evaluation (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_001.pdf">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings and some data (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.9b00303/suppl_file/jm9b00303_si_002.csv">CSV</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm9b00303_si_001.pdf"><caption><p>jm9b00303_si_001.pdf</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm9b00303_si_002.csv"><caption><p>jm9b00303_si_002.csv</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Present Address</title><p><sup>&#x000a7;</sup> W.L.: Shaanxi Institute of Traditional Chinese Medicine, Shaanxi,
China.</p></notes><notes notes-type="COI-statement" id="notes4"><p>The authors
declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>W.L., W.D., and G.Y. gratefully acknowledge financial
support by a scholarship from the China Scholarship Council CSC, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.csc.edu.cn/">http://www.csc.edu.cn/</uri>), Grants
201306300064, 201603250057, and 201406210064, respectively. The authors
thank Ron Fouchier (Erasmus Medical Center, The Netherlands) for generously
providing recombinant influenza viruses WU95 and VI75.</p></ack><glossary id="dl1"><def-list><title>Abbreviations Used</title><def-item><term>CCR2</term><def><p>CC chemokine
receptor 2</p></def></def-item><def-item><term>CCL2</term><def><p>CC chemokine ligand
2</p></def></def-item><def-item><term>CCR5</term><def><p>CC chemokine
receptor 5</p></def></def-item><def-item><term>TLC</term><def><p>thin
layer chromatography</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Palese</surname><given-names>P.</given-names></name>
<article-title>Influenza:
Old and New Threats</article-title>. <source>Nat. Med.</source>
<year>2004</year>, <volume>10</volume>, <fpage>S82</fpage>&#x02013;<lpage>S87</lpage>. <pub-id pub-id-type="doi">10.1038/nm1141</pub-id>.<pub-id pub-id-type="pmid">15577936</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Richard</surname><given-names>M.</given-names></name>; <name><surname>Fouchier</surname><given-names>R. A. M.</given-names></name>
<article-title>Influenza A Virus
Transmission via Respiratory Aerosols
or Droplets as It Relates to Pandemic Potential</article-title>. <source>FEMS Microbiol. Rev.</source>
<year>2016</year>, <volume>40</volume>, <fpage>68</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fuv039</pub-id>.<pub-id pub-id-type="pmid">26385895</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Hamilton</surname><given-names>B. S.</given-names></name>; <name><surname>Whittaker</surname><given-names>G. R.</given-names></name>; <name><surname>Daniel</surname><given-names>S.</given-names></name>
<article-title>Influenza Virus-Mediated Membrane
Fusion: Determinants of Hemagglutinin Fusogenic Activity and Experimental
Approaches for Assessing Virus Fusion</article-title>. <source>Viruses</source>
<year>2012</year>, <volume>4</volume>, <fpage>1144</fpage>&#x02013;<lpage>1168</lpage>. <pub-id pub-id-type="doi">10.3390/v4071144</pub-id>.<pub-id pub-id-type="pmid">22852045</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Guo</surname><given-names>H.</given-names></name>; <name><surname>Rabouw</surname><given-names>H.</given-names></name>; <name><surname>Slomp</surname><given-names>A.</given-names></name>; <name><surname>Dai</surname><given-names>M.</given-names></name>; <name><surname>van der
Vegt</surname><given-names>F.</given-names></name>; <name><surname>van Lent</surname><given-names>J. W. M.</given-names></name>; <name><surname>McBride</surname><given-names>R.</given-names></name>; <name><surname>Paulson</surname><given-names>J. C.</given-names></name>; <name><surname>de Groot</surname><given-names>R. J.</given-names></name>; <name><surname>van Kuppeveld</surname><given-names>F. J. M.</given-names></name>; <name><surname>de Vries</surname><given-names>E.</given-names></name>; <name><surname>de Haan</surname><given-names>C. A. M.</given-names></name>
<article-title>Kinetic
Analysis of the Influenza A Virus HA/NA Balance Reveals Contribution
OfNA to Virus-Receptor Binding and NA-Dependent Rolling on Receptor-Containing
Surfaces</article-title>. <source>PLoS Pathog.</source>
<year>2018</year>, <volume>14</volume>, <elocation-id>e1007233</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007233</pub-id>.<pub-id pub-id-type="pmid">30102740</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>de
Graaf</surname><given-names>M.</given-names></name>; <name><surname>Fouchier</surname><given-names>R. A.</given-names></name>
<article-title>Role of Receptor Binding Specificity
in Influenza A Virus Transmission and Pathogenesis</article-title>. <source>EMBO J.</source>
<year>2014</year>, <volume>33</volume>, <fpage>823</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1002/embj.201387442</pub-id>.<pub-id pub-id-type="pmid">24668228</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Ji</surname><given-names>Y.</given-names></name>; <name><surname>White</surname><given-names>Y. J.</given-names></name>; <name><surname>Hadden</surname><given-names>J. A.</given-names></name>; <name><surname>Grant</surname><given-names>O. C.</given-names></name>; <name><surname>Woods</surname><given-names>R. J.</given-names></name>
<article-title>New Insights
into Influenza A Specificity: An Evolution of Paradigms</article-title>. <source>Curr. Opin. Struct. Biol.</source>
<year>2017</year>, <volume>44</volume>, <fpage>219</fpage>&#x02013;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2017.06.001</pub-id>.<pub-id pub-id-type="pmid">28675835</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Skalickova</surname><given-names>S.</given-names></name>; <name><surname>Heger</surname><given-names>Z.</given-names></name>; <name><surname>Krejcova</surname><given-names>L.</given-names></name>; <name><surname>Pekarik</surname><given-names>V.</given-names></name>; <name><surname>Bastl</surname><given-names>K.</given-names></name>; <name><surname>Janda</surname><given-names>J.</given-names></name>; <name><surname>Kostolansky</surname><given-names>F.</given-names></name>; <name><surname>Vareckova</surname><given-names>E.</given-names></name>; <name><surname>Zitka</surname><given-names>O.</given-names></name>; <name><surname>Adam</surname><given-names>V.</given-names></name>; <name><surname>Kizek</surname><given-names>R.</given-names></name>
<article-title>Perspective
of Use
of Antiviral Peptides against Influenza Virus</article-title>. <source>Viruses</source>
<year>2015</year>, <volume>7</volume>, <fpage>5428</fpage>&#x02013;<lpage>5442</lpage>. <pub-id pub-id-type="doi">10.3390/v7102883</pub-id>.<pub-id pub-id-type="pmid">26492266</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>von
Itzstein</surname><given-names>M.</given-names></name>
<article-title>The War against Influenza: Discovery and Development
of Sialidase Inhibitors</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2007</year>, <volume>6</volume>, <fpage>967</fpage>&#x02013;<lpage>974</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2400</pub-id>.<pub-id pub-id-type="pmid">18049471</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Moscona</surname><given-names>A.</given-names></name>
<article-title>Oseltamivir
Resistance &#x02014; Disabling Our Influenza Defenses</article-title>. <source>N. Engl. J. Med.</source>
<year>2005</year>, <volume>353</volume>, <fpage>2633</fpage>&#x02013;<lpage>2636</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp058291</pub-id>.<pub-id pub-id-type="pmid">16371626</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Ernst</surname><given-names>B.</given-names></name>; <name><surname>Magnani</surname><given-names>J. L.</given-names></name>
<article-title>From Carbohydrate Leads to Glycomimetic Drugs</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2009</year>, <volume>8</volume>, <fpage>661</fpage>&#x02013;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2852</pub-id>.<pub-id pub-id-type="pmid">19629075</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Sauter</surname><given-names>N. K.</given-names></name>; <name><surname>Bednarski</surname><given-names>M. D.</given-names></name>; <name><surname>Wurzburg</surname><given-names>B. A.</given-names></name>; <name><surname>Hanson</surname><given-names>J. E.</given-names></name>; <name><surname>Whitesides</surname><given-names>G. M.</given-names></name>; <name><surname>Skehel</surname><given-names>J. J.</given-names></name>; <name><surname>Wiley</surname><given-names>D. C.</given-names></name>
<article-title>Hemagglutinins from Two Influenza
Virus Variants Bind to Sialic Acid Derivatives with Millimolar Dissociation
Constants: A 500-MHz Proton Nuclear Magnetic Resonance Study</article-title>. <source>Biochemistry</source>
<year>1989</year>, <volume>28</volume>, <fpage>8388</fpage>&#x02013;<lpage>8396</lpage>. <pub-id pub-id-type="doi">10.1021/bi00447a018</pub-id>.<pub-id pub-id-type="pmid">2605190</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Bandlow</surname><given-names>V.</given-names></name>; <name><surname>Liese</surname><given-names>S.</given-names></name>; <name><surname>Lauster</surname><given-names>D.</given-names></name>; <name><surname>Ludwig</surname><given-names>K.</given-names></name>; <name><surname>Netz</surname><given-names>R. R.</given-names></name>; <name><surname>Herrmann</surname><given-names>A.</given-names></name>; <name><surname>Seitz</surname><given-names>O.</given-names></name>
<article-title>Spatial Screening of Hemagglutinin
on Influenza A Virus Particles: Sialyl-LacNAc Displays on DNA and
PEG Scaffolds Reveal the Requirements for Bivalency Enhanced Interactions
with Weak Monovalent Binders</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2017</year>, <volume>139</volume>, <fpage>16389</fpage>&#x02013;<lpage>16397</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.7b09967</pub-id>.<pub-id pub-id-type="pmid">29052990</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Connor</surname><given-names>R. J.</given-names></name>; <name><surname>Kawaoka</surname><given-names>Y.</given-names></name>; <name><surname>Webster</surname><given-names>R. G.</given-names></name>; <name><surname>Paulson</surname><given-names>J. C.</given-names></name>
<article-title>Receptor Specificity
in Human, Avian, and Equine H2 and H3 Influenza Virus Isolates</article-title>. <source>Virology</source>
<year>1994</year>, <volume>205</volume>, <fpage>17</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1994.1615</pub-id>.<pub-id pub-id-type="pmid">7975212</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Kadam</surname><given-names>R. U.</given-names></name>; <name><surname>Wilson</surname><given-names>I. A.</given-names></name>
<article-title>A Small-Molecule Fragment That Emulates Binding of
Receptor and Broadly Neutralizing Antibodies to Influenza A Hemagglutinin</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2018</year>, <volume>115</volume>, <fpage>4240</fpage>&#x02013;<lpage>4245</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1801999115</pub-id>.<pub-id pub-id-type="pmid">29610325</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Mammen</surname><given-names>M.</given-names></name>; <name><surname>Choi</surname><given-names>S. K.</given-names></name>; <name><surname>Whitesides</surname><given-names>G. M.</given-names></name>
<article-title>Polyvalent
Interactions in Biological
Systems: Implications for Design and Use of Multivalent Ligands and
Inhibitors</article-title>. <source>Angew. Chem., Int. Ed. Engl.</source>
<year>1998</year>, <volume>37</volume>, <fpage>2754</fpage>&#x02013;<lpage>2794</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1521-3773(19981102)37:20&#x0003c;2754::AID-ANIE2754&#x0003e;3.0.CO;2-3</pub-id>.<pub-id pub-id-type="pmid">29711117</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Peng</surname><given-names>W.</given-names></name>; <name><surname>de Vries</surname><given-names>R. P.</given-names></name>; <name><surname>Grant</surname><given-names>O. C.</given-names></name>; <name><surname>Thompson</surname><given-names>A. J.</given-names></name>; <name><surname>McBride</surname><given-names>R.</given-names></name>; <name><surname>Tsogtbaatar</surname><given-names>B.</given-names></name>; <name><surname>Lee</surname><given-names>P. S.</given-names></name>; <name><surname>Razi</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>I. A.</given-names></name>; <name><surname>Woods</surname><given-names>R. J.</given-names></name>; <name><surname>Paulson</surname><given-names>J. C.</given-names></name>
<article-title>Recent H3N2 Viruses Have Evolved
Specificity for Extended, Branched Human-Type Receptors, Conferring
Potential for Increased Avidity</article-title>. <source>Cell Host Microbe</source>
<year>2017</year>, <volume>21</volume>, <fpage>23</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.11.004</pub-id>.<pub-id pub-id-type="pmid">28017661</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Cecioni</surname><given-names>S.</given-names></name>; <name><surname>Imberty</surname><given-names>A.</given-names></name>; <name><surname>Vidal</surname><given-names>S.</given-names></name>
<article-title>Glycomimetics
versus Multivalent
Glycoconjugates for the Design of High Affinity Lectin Ligands</article-title>. <source>Chem. Rev.</source>
<year>2015</year>, <volume>115</volume>, <fpage>525</fpage>&#x02013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1021/cr500303t</pub-id>.<pub-id pub-id-type="pmid">25495138</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Parera
Pera</surname><given-names>N. P.</given-names></name>; <name><surname>Branderhorst</surname><given-names>H. M.</given-names></name>; <name><surname>Kooij</surname><given-names>R.</given-names></name>; <name><surname>Maierhofer</surname><given-names>C.</given-names></name>; <name><surname>van der Kaaden</surname><given-names>M.</given-names></name>; <name><surname>Liskamp</surname><given-names>R. M. J.</given-names></name>; <name><surname>Wittmann</surname><given-names>V.</given-names></name>; <name><surname>Ruijtenbeek</surname><given-names>R.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Rapid Screening of Lectins for Multivalency Effects
with a Glycodendrimer Microarray</article-title>. <source>ChemBioChem</source>
<year>2010</year>, <volume>11</volume>, <fpage>1896</fpage>&#x02013;<lpage>1904</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201000340</pub-id>.<pub-id pub-id-type="pmid">20672284</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Wittmann</surname><given-names>V.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Bridging Lectin
Binding Sites by Multivalent Carbohydrates</article-title>. <source>Chem. Soc. Rev.</source>
<year>2013</year>, <volume>42</volume>, <fpage>4492</fpage>&#x02013;<lpage>4503</lpage>. <pub-id pub-id-type="doi">10.1039/c3cs60089k</pub-id>.<pub-id pub-id-type="pmid">23598793</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Bernardi</surname><given-names>A.</given-names></name>; <name><surname>Jimenez-Barbero</surname><given-names>J.</given-names></name>; <name><surname>Casnati</surname><given-names>A.</given-names></name>; <name><surname>De Castro</surname><given-names>C. De</given-names></name>; <name><surname>Darbre</surname><given-names>T.</given-names></name>; <name><surname>Fieschi</surname><given-names>F.</given-names></name>; <name><surname>Finne</surname><given-names>J.</given-names></name>; <name><surname>Funken</surname><given-names>H.</given-names></name>; <name><surname>Jaeger</surname><given-names>K.-E.-E.</given-names></name>; <name><surname>Lahmann</surname><given-names>M.</given-names></name>; <name><surname>Lindhorst</surname><given-names>T. K.</given-names></name>; <name><surname>Marradi</surname><given-names>M.</given-names></name>; <name><surname>Messner</surname><given-names>P.</given-names></name>; <name><surname>Molinaro</surname><given-names>A.</given-names></name>; <name><surname>Murphy</surname><given-names>P. V.</given-names></name>; <name><surname>Nativi</surname><given-names>C.</given-names></name>; <name><surname>Oscarson</surname><given-names>S.</given-names></name>; <name><surname>Penades</surname><given-names>S.</given-names></name>; <name><surname>Peri</surname><given-names>F.</given-names></name>; et al. <article-title>Multivalent Glycoconjugates as Anti-Pathogenic Agents</article-title>. <source>Chem. Soc. Rev.</source>
<year>2013</year>, <volume>42</volume>, <fpage>4709</fpage>&#x02013;<lpage>4727</lpage>. <pub-id pub-id-type="doi">10.1039/C2CS35408J</pub-id>.<pub-id pub-id-type="pmid">23254759</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Kiessling</surname><given-names>L. L.</given-names></name>; <name><surname>Gestwicki</surname><given-names>J. E.</given-names></name>; <name><surname>Strong</surname><given-names>L. E.</given-names></name>
<article-title>Synthetic Multivalent Ligands as
Probes of Signal Transduction</article-title>. <source>Angew. Chem.,
Int. Ed.</source>
<year>2006</year>, <volume>45</volume>, <fpage>2348</fpage>&#x02013;<lpage>2368</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200502794</pub-id>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Maximising
Multivalency Effects in Protein-Carbohydrate Interactions</article-title>. <source>Org. Biomol. Chem.</source>
<year>2009</year>, <volume>7</volume>, <fpage>2013</fpage>&#x02013;<lpage>2025</lpage>. <pub-id pub-id-type="doi">10.1039/b901828j</pub-id>.<pub-id pub-id-type="pmid">19421435</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Lu</surname><given-names>W.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Carbohydrate&#x02013;Protein Interactions and Multivalency:
Implications for the Inhibition of Influenza A Virus Infections</article-title>. <source>Expert Opin. Drug Discovery</source>
<year>2019</year>, <volume>14</volume>, <fpage>387</fpage>&#x02013;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2019.1573813</pub-id>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Matrosovich</surname><given-names>M. N.</given-names></name>; <name><surname>Mochalova</surname><given-names>L. V.</given-names></name>; <name><surname>Marinina</surname><given-names>V. P.</given-names></name>; <name><surname>Byramova</surname><given-names>N. E.</given-names></name>; <name><surname>Bovin</surname><given-names>N. V.</given-names></name>
<article-title>Synthetic
Polymeric Inhibitors of Influenza Virus Receptor-Binding Activity
Suppress Virus Replication</article-title>. <source>FEBS Lett.</source>
<year>1990</year>, <volume>272</volume>, <fpage>209</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(90)80486-3</pub-id>.<pub-id pub-id-type="pmid">1699804</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Lees</surname><given-names>W. J.</given-names></name>; <name><surname>Spaltenstein</surname><given-names>A.</given-names></name>; <name><surname>Kingery-Wood</surname><given-names>J. E.</given-names></name>; <name><surname>Whitesides</surname><given-names>G. M.</given-names></name>
<article-title>Polyacrylamides
Bearing Pendant A-Sialoside Groups Strongly Inhibit Agglutination
of Erythrocytes by Influenza A Virus: Multivalency and Steric Stabilization
of Particulate Biological Systems</article-title>. <source>J. Med. Chem.</source>
<year>1994</year>, <volume>37</volume>, <fpage>3419</fpage>&#x02013;<lpage>3433</lpage>. <pub-id pub-id-type="doi">10.1021/jm00046a027</pub-id>.<pub-id pub-id-type="pmid">7932570</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Choi</surname><given-names>S. K.</given-names></name>; <name><surname>Mammen</surname><given-names>M.</given-names></name>; <name><surname>Whitesides</surname><given-names>G. M.</given-names></name>
<article-title>Generation
and in Situ Evaluation
of Libraries of Poly(Acrylic Acid) Presenting Sialosides as Side Chains
as Polyvalent Inhibitors of Influenza- Mediated Hemagglutination</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1997</year>, <volume>119</volume>, <fpage>4103</fpage>&#x02013;<lpage>4111</lpage>. <pub-id pub-id-type="doi">10.1021/ja963519x</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Kamitakahara</surname><given-names>H.</given-names></name>; <name><surname>Suzuki</surname><given-names>T.</given-names></name>; <name><surname>Nishigori</surname><given-names>N.</given-names></name>; <name><surname>Suzuki</surname><given-names>Y.</given-names></name>; <name><surname>Kanie</surname><given-names>O.</given-names></name>; <name><surname>Wong</surname><given-names>C.-H.</given-names></name>
<article-title>A Lysoganglioside/Poly-<sc>l</sc>-Glutamic Acid</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>1998</year>, <volume>37</volume>, <fpage>1524</fpage>&#x02013;<lpage>1528</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1521-3773(19980619)37:11&#x0003c;1524::AID-ANIE1524&#x0003e;3.0.CO;2-D</pub-id>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Papp</surname><given-names>I.</given-names></name>; <name><surname>Sieben</surname><given-names>C.</given-names></name>; <name><surname>Sisson</surname><given-names>A. L.</given-names></name>; <name><surname>Kostka</surname><given-names>J.</given-names></name>; <name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name>; <name><surname>Ludwig</surname><given-names>K.</given-names></name>; <name><surname>Herrmann</surname><given-names>A.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Inhibition of Influenza
Virus Activity by Multivalent Glycoarchitectures with Matched Sizes</article-title>. <source>ChemBioChem</source>
<year>2011</year>, <volume>12</volume>, <fpage>887</fpage>&#x02013;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1002/cbic.201000776</pub-id>.<pub-id pub-id-type="pmid">21384484</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Bhatia</surname><given-names>S.</given-names></name>; <name><surname>Lauster</surname><given-names>D.</given-names></name>; <name><surname>Bardua</surname><given-names>M.</given-names></name>; <name><surname>Ludwig</surname><given-names>K.</given-names></name>; <name><surname>Angioletti-Uberti</surname><given-names>S.</given-names></name>; <name><surname>Popp</surname><given-names>N.</given-names></name>; <name><surname>Hoffmann</surname><given-names>U.</given-names></name>; <name><surname>Paulus</surname><given-names>F.</given-names></name>; <name><surname>Budt</surname><given-names>M.</given-names></name>; <name><surname>Stadtm&#x000fc;ller</surname><given-names>M.</given-names></name>; <name><surname>Wolff</surname><given-names>T.</given-names></name>; <name><surname>Hamann</surname><given-names>A.</given-names></name>; <name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name>; <name><surname>Herrmann</surname><given-names>A.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Linear Polysialoside Outperforms
Dendritic Analogs for Inhibition of Influenza Virus Infection in Vitro
and in Vivo</article-title>. <source>Biomaterials</source>
<year>2017</year>, <volume>138</volume>, <fpage>22</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.05.028</pub-id>.<pub-id pub-id-type="pmid">28550754</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Wu</surname><given-names>P.</given-names></name>; <name><surname>Gao</surname><given-names>G. F.</given-names></name>; <name><surname>Cheng</surname><given-names>S.</given-names></name>
<article-title>Carbohydrate-Functionalized Chitosan
Fiber for Influenza Virus Capture</article-title>. <source>Biomacromolecules</source>
<year>2011</year>, <volume>12</volume>, <fpage>3962</fpage>&#x02013;<lpage>3969</lpage>. <pub-id pub-id-type="doi">10.1021/bm200970x</pub-id>.<pub-id pub-id-type="pmid">21978096</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Yeh</surname><given-names>H. W.</given-names></name>; <name><surname>Lin</surname><given-names>T. S.</given-names></name>; <name><surname>Wang</surname><given-names>H. W.</given-names></name>; <name><surname>Cheng</surname><given-names>H. W.</given-names></name>; <name><surname>Liu</surname><given-names>D. Z.</given-names></name>; <name><surname>Liang</surname><given-names>P. H.</given-names></name>
<article-title>S-Linked Sialyloligosaccharides
Bearing Liposomes and
Micelles as Influenza Virus Inhibitors</article-title>. <source>Org.
Biomol. Chem.</source>
<year>2015</year>, <volume>13</volume>, <fpage>11518</fpage>&#x02013;<lpage>11528</lpage>. <pub-id pub-id-type="doi">10.1039/C5OB01376C</pub-id>.<pub-id pub-id-type="pmid">26464117</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Glick</surname><given-names>G. D.</given-names></name>; <name><surname>Knowles</surname><given-names>J. R.</given-names></name>
<article-title>Molecular Recognition
of Bivalent Sialosides by Influenza
Virus</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1991</year>, <volume>113</volume>, <fpage>4701</fpage>&#x02013;<lpage>4703</lpage>. <pub-id pub-id-type="doi">10.1021/ja00012a060</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Glick</surname><given-names>G. D.</given-names></name>; <name><surname>Toogood</surname><given-names>P. L.</given-names></name>; <name><surname>Wiley</surname><given-names>D. C.</given-names></name>; <name><surname>Skehel</surname><given-names>J. J.</given-names></name>; <name><surname>Knowles</surname><given-names>J. R.</given-names></name>
<article-title>Ligand
Recognition by Influenza Virus</article-title>. <source>J. Biol. Chem.</source>
<year>1991</year>, <volume>266</volume>, <fpage>23660</fpage>&#x02013;<lpage>23669</lpage>.<pub-id pub-id-type="pmid">1748643</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Sabesan</surname><given-names>S.</given-names></name>; <name><surname>Duus</surname><given-names>J. O.</given-names></name>; <name><surname>Domaille</surname><given-names>P.</given-names></name>; <name><surname>Kelm</surname><given-names>S.</given-names></name>; <name><surname>Paulson</surname><given-names>J. C.</given-names></name>
<article-title>Synthesis
of Cluster Sialoside Inhibitors for Influenza Virus</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1991</year>, <volume>113</volume>, <fpage>5865</fpage>&#x02013;<lpage>5866</lpage>. <pub-id pub-id-type="doi">10.1021/ja00015a052</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Roy</surname><given-names>R.</given-names></name>; <name><surname>Zanini</surname><given-names>D.</given-names></name>; <name><surname>Meunier</surname><given-names>S. J.</given-names></name>; <name><surname>Romanowska</surname><given-names>A.</given-names></name>
<article-title>Solid-Phase
Synthesis of Dendritic Sialoside Inhibitors of Influenza a Virus Hemagglutin</article-title>. <source>J. Chem. Soc., Chem. Commun.</source>
<year>1993</year>, <fpage>1869</fpage>&#x02013;<lpage>1872</lpage>. <pub-id pub-id-type="doi">10.1039/c39930001869</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Ohta</surname><given-names>T.</given-names></name>; <name><surname>Miura</surname><given-names>N.</given-names></name>; <name><surname>Fujitani</surname><given-names>N.</given-names></name>; <name><surname>Nakajima</surname><given-names>F.</given-names></name>; <name><surname>Niikura</surname><given-names>K.</given-names></name>; <name><surname>Sadamoto</surname><given-names>R.</given-names></name>; <name><surname>Guo</surname><given-names>C. T.</given-names></name>; <name><surname>Suzuki</surname><given-names>T.</given-names></name>; <name><surname>Suzuki</surname><given-names>Y.</given-names></name>; <name><surname>Monde</surname><given-names>K.</given-names></name>; <name><surname>Nishimura</surname><given-names>S. I.</given-names></name>
<article-title>Glycotentacles: Synthesis of Cyclic
Glycopeptides, toward a Tailored Blocker of Influenza Virus Hemagglutinin</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2003</year>, <volume>42</volume>, <fpage>5186</fpage>&#x02013;<lpage>5189</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200351640</pub-id>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Marra</surname><given-names>A.</given-names></name>; <name><surname>Moni</surname><given-names>L.</given-names></name>; <name><surname>Pazzi</surname><given-names>D.</given-names></name>; <name><surname>Corallini</surname><given-names>A.</given-names></name>; <name><surname>Bridi</surname><given-names>D.</given-names></name>; <name><surname>Dondoni</surname><given-names>A.</given-names></name>
<article-title>Synthesis of Sialoclusters Appended
to Calix[4]Arene Platforms via Multiple Azide-Alkyne Cycloaddition.
New Inhibitors of Hemagglutination and Cytopathic Effect Mediated
by BK and Influenza A Viruses</article-title>. <source>Org. Biomol.
Chem.</source>
<year>2008</year>, <volume>6</volume>, <fpage>1396</fpage>&#x02013;<lpage>1409</lpage>. <pub-id pub-id-type="doi">10.1039/b800598b</pub-id>.<pub-id pub-id-type="pmid">18385846</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Waldmann</surname><given-names>M.</given-names></name>; <name><surname>Jirmann</surname><given-names>R.</given-names></name>; <name><surname>Hoelscher</surname><given-names>K.</given-names></name>; <name><surname>Wienke</surname><given-names>M.</given-names></name>; <name><surname>Niemeyer</surname><given-names>F. C.</given-names></name>; <name><surname>Rehders</surname><given-names>D.</given-names></name>; <name><surname>Meyer</surname><given-names>B.</given-names></name>
<article-title>A Nanomolar
Multivalent Ligand as
Entry Inhibitor of the Hemagglutinin of Avian Influenza</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2014</year>, <volume>136</volume>, <fpage>783</fpage>&#x02013;<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1021/ja410918a</pub-id>.<pub-id pub-id-type="pmid">24377426</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Yamabe</surname><given-names>M.</given-names></name>; <name><surname>Kaihatsu</surname><given-names>K.</given-names></name>; <name><surname>Ebara</surname><given-names>Y.</given-names></name>
<article-title>Sialyllactose-Modified Three-Way
Junction DNA as Binding Inhibitor of Influenza Virus Hemagglutinin</article-title>. <source>Bioconjugate Chem.</source>
<year>2018</year>, <volume>29</volume>, <fpage>1490</fpage>&#x02013;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00045</pub-id>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Pieters</surname><given-names>R. J.</given-names></name>; <name><surname>Cuntze</surname><given-names>J.</given-names></name>; <name><surname>Bonnet</surname><given-names>M.</given-names></name>; <name><surname>Diederich</surname><given-names>F.</given-names></name>
<article-title>Enantioselective
Recognition with C-3-Symmetric Cage-like Receptors in Solution and
on a Stationary Phase</article-title>. <source>J. Chem. Soc., Perkin
Trans. 2</source>
<year>1997</year>, <fpage>1891</fpage>&#x02013;<lpage>1900</lpage>. <pub-id pub-id-type="doi">10.1039/a702627g</pub-id>.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Pertici</surname><given-names>F.</given-names></name>; <name><surname>De Mol</surname><given-names>N. J.</given-names></name>; <name><surname>Kemmink</surname><given-names>J.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Optimizing Divalent
Inhibitors of Pseudomonas Aeruginosa Lectin LecA by Using a Rigid
Spacer</article-title>. <source>Chem.&#x02014;Eur. J.</source>
<year>2013</year>, <volume>19</volume>, <fpage>16923</fpage>&#x02013;<lpage>16927</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201303463</pub-id>.<pub-id pub-id-type="pmid">24307357</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Yu</surname><given-names>G.</given-names></name>; <name><surname>Vicini</surname><given-names>A. C.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Assembling
of Divalent Ligands and
Their Effect on Divalent Binding to Pseudomonas Aeruginosa Lectin
LecA</article-title>. <source>J. Org. Chem.</source>
<year>2019</year>, <volume>84</volume>, <fpage>2470</fpage>&#x02013;<lpage>2488</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.8b02727</pub-id>.<pub-id pub-id-type="pmid">30681333</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Visini</surname><given-names>R.</given-names></name>; <name><surname>Jin</surname><given-names>X.</given-names></name>; <name><surname>Bergmann</surname><given-names>M.</given-names></name>; <name><surname>Michaud</surname><given-names>G.</given-names></name>; <name><surname>Pertici</surname><given-names>F.</given-names></name>; <name><surname>Fu</surname><given-names>O.</given-names></name>; <name><surname>Pukin</surname><given-names>A.</given-names></name>; <name><surname>Branson</surname><given-names>T. R.</given-names></name>; <name><surname>Thies-Weesie</surname><given-names>D. M. E.</given-names></name>; <name><surname>Kemmink</surname><given-names>J.</given-names></name>; <name><surname>Gillon</surname><given-names>E.</given-names></name>; <name><surname>Imberty</surname><given-names>A.</given-names></name>; <name><surname>Stocker</surname><given-names>A.</given-names></name>; <name><surname>Darbre</surname><given-names>T.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>; <name><surname>Reymond</surname><given-names>J.-L.</given-names></name>
<article-title>Structural Insight
into Multivalent Galactoside Binding to Pseudomonas Aeruginosa Lectin
LecA</article-title>. <source>ACS Chem. Biol.</source>
<year>2015</year>, <volume>10</volume>, <fpage>2455</fpage>&#x02013;<lpage>2462</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.5b00302</pub-id>.<pub-id pub-id-type="pmid">26295304</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Haksar</surname><given-names>D.</given-names></name>; <name><surname>de Poel</surname><given-names>E.</given-names></name>; <name><surname>van Ufford</surname><given-names>L. Q.</given-names></name>; <name><surname>Bhatia</surname><given-names>S.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>; <name><surname>Beekman</surname><given-names>J. M.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>
<article-title>Strong
Inhibition of Cholera Toxin
B Subunit by Affordable, Polymer-Based Multivalent Inhibitors</article-title>. <source>Bioconjugate Chem.</source>
<year>2019</year>, <volume>30</volume>, <fpage>785</fpage>&#x02013;<lpage>792</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00902</pub-id>.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>McArthur</surname><given-names>J. B.</given-names></name>; <name><surname>Yu</surname><given-names>H.</given-names></name>; <name><surname>Zeng</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>
<article-title>Converting Pasteurella Multocida
&#x00391;2-3-Sialyltransferase 1 (PmST1) to a Regioselective &#x00391;2-6-Sialyltransferase
by Saturation Mutagenesis and Regioselective Screening</article-title>. <source>Org. Biomol. Chem.</source>
<year>2017</year>, <volume>15</volume>, <fpage>1700</fpage>&#x02013;<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1039/C6OB02702D</pub-id>.<pub-id pub-id-type="pmid">28134951</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Xiong</surname><given-names>X.</given-names></name>; <name><surname>Xiao</surname><given-names>H.</given-names></name>; <name><surname>Martin</surname><given-names>S. R.</given-names></name>; <name><surname>Coombs</surname><given-names>P. J.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Collins</surname><given-names>P. J.</given-names></name>; <name><surname>Vachieri</surname><given-names>S. G.</given-names></name>; <name><surname>Walker</surname><given-names>P. A.</given-names></name>; <name><surname>Lin</surname><given-names>Y. P.</given-names></name>; <name><surname>McCauley</surname><given-names>J. W.</given-names></name>; <name><surname>Gamblin</surname><given-names>S. J.</given-names></name>; <name><surname>Skehel</surname><given-names>J. J.</given-names></name>
<article-title>Enhanced Human Receptor
Binding by H5 Haemagglutinins</article-title>. <source>Virology</source>
<year>2014</year>, <volume>456&#x02013;457</volume>, <fpage>179</fpage>&#x02013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2014.03.008</pub-id>.</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Liese</surname><given-names>S.</given-names></name>; <name><surname>Netz</surname><given-names>R. R.</given-names></name>
<article-title>Influence of Length and Flexibility of Spacers on the
Binding Affinity of Divalent Ligands</article-title>. <source>Beilstein
J. Org. Chem.</source>
<year>2015</year>, <volume>11</volume>, <fpage>804</fpage>&#x02013;<lpage>816</lpage>. <pub-id pub-id-type="doi">10.3762/bjoc.11.90</pub-id>.<pub-id pub-id-type="pmid">26124882</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Nemanichvili</surname><given-names>N.</given-names></name>; <name><surname>Tomris</surname><given-names>I.</given-names></name>; <name><surname>Turner</surname><given-names>H. L.</given-names></name>; <name><surname>McBride</surname><given-names>R.</given-names></name>; <name><surname>Grant</surname><given-names>O. C.</given-names></name>; <name><surname>van der
Woude</surname><given-names>R.</given-names></name>; <name><surname>Aldosari</surname><given-names>M. H.</given-names></name>; <name><surname>Pieters</surname><given-names>R. J.</given-names></name>; <name><surname>Woods</surname><given-names>R. J.</given-names></name>; <name><surname>Paulson</surname><given-names>J. C.</given-names></name>; <name><surname>Boons</surname><given-names>G.-J.</given-names></name>; <name><surname>Ward</surname><given-names>A. B.</given-names></name>; <name><surname>Verheije</surname><given-names>M. H.</given-names></name>; <name><surname>de Vries</surname><given-names>R. P.</given-names></name>
<article-title>Fluorescent Trimeric Hemagglutinins Reveal Multivalent
Receptor Binding Properties</article-title>. <source>J. Mol. Biol.</source>
<year>2019</year>, <volume>431</volume>, <fpage>842</fpage>&#x02013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2018.12.014</pub-id>.<pub-id pub-id-type="pmid">30597163</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Kale</surname><given-names>R. R.</given-names></name>; <name><surname>Mukundan</surname><given-names>H.</given-names></name>; <name><surname>Price</surname><given-names>D. N.</given-names></name>; <name><surname>Harris</surname><given-names>J. F.</given-names></name>; <name><surname>Lewallen</surname><given-names>D. M.</given-names></name>; <name><surname>Swanson</surname><given-names>B. I.</given-names></name>; <name><surname>Schmidt</surname><given-names>J. G.</given-names></name>; <name><surname>Iyer</surname><given-names>S. S.</given-names></name>
<article-title>Detection of Intact
Influenza Viruses Using Biotinylated Biantennary S-Sialosides</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2008</year>, <volume>130</volume>, <fpage>8169</fpage>&#x02013;<lpage>8171</lpage>. <pub-id pub-id-type="doi">10.1021/ja800842v</pub-id>.<pub-id pub-id-type="pmid">18529007</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Spjut</surname><given-names>S.</given-names></name>; <name><surname>Qian</surname><given-names>W.</given-names></name>; <name><surname>Bauer</surname><given-names>J.</given-names></name>; <name><surname>Storm</surname><given-names>R.</given-names></name>; <name><surname>Fr&#x000e4;ngsmyr</surname><given-names>L.</given-names></name>; <name><surname>Stehle</surname><given-names>T.</given-names></name>; <name><surname>Arnberg</surname><given-names>N.</given-names></name>; <name><surname>Elofsson</surname><given-names>M.</given-names></name>
<article-title>A Potent Trivalent
Sialic Acid Inhibitor of Adenovirus Type 37 Infection of Human Corneal
Cells</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2011</year>, <volume>50</volume>, <fpage>6519</fpage>&#x02013;<lpage>6521</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201101559</pub-id>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Pahimanolis</surname><given-names>N.</given-names></name>; <name><surname>Vesterinen</surname><given-names>A.-H.</given-names></name>; <name><surname>Rich</surname><given-names>J.</given-names></name>; <name><surname>Seppala</surname><given-names>J.</given-names></name>
<article-title>Modification of Dextran
Using Click-Chemistry Approach in Aqueous Media</article-title>. <source>Carbohydr. Polym.</source>
<year>2010</year>, <volume>82</volume>, <fpage>78</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2010.04.025</pub-id>.</mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Moni</surname><given-names>L.</given-names></name>; <name><surname>Ciogli</surname><given-names>A.</given-names></name>; <name><surname>D&#x02019;Acquarica</surname><given-names>I.</given-names></name>; <name><surname>Dondoni</surname><given-names>A.</given-names></name>; <name><surname>Gasparrini</surname><given-names>F.</given-names></name>; <name><surname>Marra</surname><given-names>A.</given-names></name>
<article-title>Synthesis of Sugar-Based
Silica Gels by Copper-Catalysed Azide-Alkyne
Cycloaddition via a Single-Step Azido-Activated Silica Intermediate
and the Use of the Gels in Hydrophilic Interaction Chromatography</article-title>. <source>Chem. - Eur. J.</source>
<year>2010</year>, <volume>16</volume>, <fpage>5712</fpage>&#x02013;<lpage>5722</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201000106</pub-id>.<pub-id pub-id-type="pmid">20391561</pub-id></mixed-citation></ref></ref-list></back></article>